Ipamorelin vs CJC-1295: How These Two GH-Axis Peptides Differ (Australia Research Guide)

Ipamorelin and CJC-1295 are the two most-studied growth hormone (GH) secretagogues in peptide research, and they are frequently confused because both raise GH. They are, however, fundamentally different molecules acting on different receptors through different mechanisms. Choosing between them for a research model depends entirely on which part of the GH axis you want to interrogate.

The single sentence that captures the difference:

The core distinction Ipamorelin is a GHRP — a selective ghrelin-receptor (GHSR-1a) agonist that triggers a sharp, pulsatile burst of GH with minimal off-target hormone effects. CJC-1295 is a GHRH analogue — it mimics growth-hormone-releasing hormone to raise the baseline GH/IGF-1 signal, briefly (no-DAC, ~30 min) or for days (with DAC, ~6–8 days). One drives the pulse; the other sets the tone.

This page is about choosing between them. If your research question is about using the two together — the synergy, the stack, combined dosing — that is a different topic covered in full by the CJC-1295 & Ipamorelin combination research guide →. Below, we keep the two compounds side by side and individual.

Half-life and receptor values above are well-established, class-level pharmacology for these compounds. Doses are intentionally omitted here — this is a comparison of mechanism, not a dosing page.

The reason these two peptides behave differently comes down to which receptor on the pituitary somatotroph they activate, and the two receptors trigger different intracellular cascades:

• CJC-1295 (GHRH analogue) → GHRH receptor. Like native GHRH, it raises intracellular cAMP via the Gs/adenylyl-cyclase/PKA pathway. This both synthesises new GH and promotes its secretion, and it sensitises the somatotroph to further stimulation. The effect is best described as raising the GH "set point" or baseline tone.
• Ipamorelin (GHRP) → GHSR-1a (ghrelin receptor). This is a different receptor entirely. It signals through phospholipase C and PKC, mobilising intracellular calcium and triggering the rapid release of stored GH vesicles. The result is a sharp pulse rather than a sustained elevation.

In short: a GHRH analogue and a GHRP are not interchangeable tools acting through the same door. They open two different doors. That is precisely why, in combination research, they are studied together for synergy — but for an individual-compound research question, the receptor you want to probe decides the peptide.

Why "GHRP" and "GHRH analogue" are not the same thing GHRP = growth-hormone-releasing peptide, acting on the ghrelin receptor (GHSR-1a) — Ipamorelin, GHRP-2, GHRP-6, hexarelin belong here. GHRH analogue = a mimic of growth-hormone-releasing hormone, acting on the GHRH receptor — CJC-1295, sermorelin, tesamorelin belong here. The naming is one letter apart but the receptor is completely different.

One reason CJC-1295 is harder to summarise than Ipamorelin is that it exists in two pharmacokinetically distinct forms. Ipamorelin has a single, fixed profile (~2-hour half-life); CJC-1295 does not.

The long-acting, albumin-binding DAC form has been characterised in human research as producing prolonged, multi-day elevation of GH and IGF-1 (Teichman et al., J Clin Endocrinol Metab 2006). This matters for the comparison because it changes how cleanly CJC-1295 contrasts with Ipamorelin. Against no-DAC CJC-1295, the contrast is mechanism-only — both produce short-lived effects, but through different receptors. Against DAC CJC-1295, the contrast is both mechanism and duration — a multi-day baseline shift versus Ipamorelin's brief pulse. The DAC formulation is what gives CJC-1295 its signature long half-life that Ipamorelin has no equivalent of.

Where CJC-1295 is defined by its pharmacokinetics, Ipamorelin is defined by its selectivity. It was developed specifically as a GHRP that releases GH without the off-target hormonal effects that limited earlier-generation GHRPs.

The earlier GHRPs — GHRP-2 and GHRP-6 — are potent GH releasers, but they also stimulate cortisol, ACTH and prolactin, which confounds any study trying to isolate GH-axis effects. In the research that introduced it, Ipamorelin produced robust GH release with little or no effect on cortisol, ACTH or prolactin at GH-effective doses — the property that made it attractive as a clean research tool (Raun et al., Eur J Endocrinol 1998).

Selectivity is a GHRP property, not a GHRH-analogue property The cortisol/prolactin selectivity story applies to Ipamorelin as a GHRP — it is the differentiator within the GHRP class (versus GHRP-2/GHRP-6). CJC-1295, being a GHRH analogue, never engaged the ghrelin pathway in the first place, so the cortisol/prolactin comparison does not frame it the same way. When researchers say "Ipamorelin is selective," they mean selective among GHRPs.

So the selectivity axis is not really "Ipamorelin vs CJC-1295" — it is "Ipamorelin vs older GHRPs." CJC-1295's distinguishing axis is duration and baseline elevation. Each peptide's headline property lives on a different axis, which is exactly why a side-by-side table (above) can mislead if read as a simple "winner" scorecard.

Because the two compounds probe different parts of the GH axis, the research question dictates the choice. As a decision aid (research-model framing, not dosing guidance):

Studying them together instead of choosing? Many GH-axis protocols deliberately combine a GHRH analogue with a GHRP to exploit their synergy, rather than picking one. That is a separate research topic — mechanism of the synergy, combined protocols, and reconstitution are covered in full in the CJC-1295 & Ipamorelin combination research guide →. This page is intentionally about the individual, head-to-head comparison.

What is the main difference between Ipamorelin and CJC-1295?

They act on different receptors. Ipamorelin is a GHRP — a selective ghrelin-receptor (GHSR-1a) agonist that triggers a sharp, pulsatile GH release. CJC-1295 is a GHRH analogue that acts on the GHRH receptor to raise baseline GH and IGF-1. Ipamorelin drives the pulse; CJC-1295 sets the tone.

Is Ipamorelin a GHRH or a GHRP?

Ipamorelin is a GHRP (growth-hormone-releasing peptide), in the same class as GHRP-2 and GHRP-6, acting on the ghrelin receptor. CJC-1295 is the GHRH analogue, in the same class as sermorelin and tesamorelin.

Which has the longer half-life?

CJC-1295 with DAC, by far — roughly 6–8 days, because a reactive group binds endogenous albumin after injection. Ipamorelin's half-life is around 2 hours. CJC-1295 without DAC (Mod-GRF 1-29) is the exception: it is short-acting at about 30 minutes.

Why is Ipamorelin called "selective"?

Selective among GHRPs. Earlier GHRPs (GHRP-2, GHRP-6) release GH but also raise cortisol, ACTH and prolactin. Ipamorelin releases GH with minimal effect on those hormones at GH-effective doses, making it a cleaner research tool. The term refers to its advantage within the GHRP class, not a comparison to CJC-1295.

Should I choose Ipamorelin or CJC-1295 for my research?

It depends on the receptor and dynamics you want to study. Use Ipamorelin to probe the ghrelin-receptor pathway or to isolate a clean GH pulse; use CJC-1295 to probe GHRH-receptor signalling or to sustain baseline GH/IGF-1 (DAC for multi-day elevation, no-DAC for short pulses). See the decision table above.

Can I use Ipamorelin and CJC-1295 together?

Combining a GHRP with a GHRH analogue is a well-studied research approach because the two pathways act synergistically — but that is a different topic from choosing between them. The combination's mechanism, protocols and reconstitution are covered in the CJC-1295 & Ipamorelin combination research guide.

OzPeps supplies research-grade Ipamorelin and CJC-1295 Australia-wide with Certificate of Analysis documentation and Express Post dispatch, for laboratory research use only.

Ipamorelin 10mg → · CJC-1295 10mg →

Studying them together? See the CJC-1295 & Ipamorelin combination research guide → for synergy, protocols and reconstitution.

All Ipamorelin and CJC-1295 products sold by OzPeps are supplied strictly for laboratory and in-vitro research purposes. They are research-grade materials, NOT FOR HUMAN CONSUMPTION, are not TGA-approved therapeutic goods, and are not intended for human or animal use, diagnosis, or treatment. Nothing on this page is medical advice or a human-dosing recommendation. Researchers are responsible for compliance with all applicable Australian regulations.